欧洲药品管理局(EMA)在其官方网站发布消息称,奥麦罗制药(Omeros)的爱尔兰子公司已正式提交请求,要求该机构对其于6月25日发布的关于药物Yartemlea的评估意见进行重新审查。
欧洲药品管理局(EMA)在其官方网站发布消息称,奥麦罗制药(Omeros)的爱尔兰子公司已正式提交请求,要求该机构对其于6月25日发布的关于药物Yartemlea的评估意见进行重新审查。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.